AIRNA
AIRNA is a biotech company developing RNA editing therapeutics for rare and common diseases. Its lead product candidate, AIR-001, targets Alpha-1 antitrypsin deficiency (AATD), aiming to provide a functional cure. The company's proprietary platform allows for precise RNA editing with potent, durable, and safe treatment.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $155M
Date: 01-Apr-2025
Investors: Venrock Healthcare Capital Partners, Forbion Growth, RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital
Markets: Biotechnology, RNA Editing, Rare Disease, Genetic Medicine
HQ: Cambridge, Massachusetts, United States
Founded: 2021
Website: https://www.airna.com/
LinkedIn: https://www.linkedin.com/company/airna-bio
Crunchbase: https://www.crunchbase.com/organization/airna
Leave a Comment
Comments
No comments yet.